|
Gubbio Study Five-year Follow-up: Lithium Countertransport, Blood Pressure, and Other Variables Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about Gubbio Study Five-year Follow-up: Lithium Countertransport, Blood Pressure, and Other Variables conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Gubbio Study Five-year Follow-up: Lithium Countertransport, Blood Pressure, and Other Variables Clinical research trials and Gubbio Study Five-year Follow-up: Lithium Countertransport, Blood Pressure, and Other Variables health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Gubbio Study Five-year Follow-up: Lithium Countertransport, Blood Pressure, and Other Variables. Gubbio Study Five-year Follow-up: Lithium Countertransport, Blood Pressure, and Other Variables Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a Gubbio Study Five-year Follow-up: Lithium Countertransport, Blood Pressure, and Other Variables clinical trial. Human subjects often get the best healthcare possible for their Gubbio Study Five-year Follow-up: Lithium Countertransport, Blood Pressure, and Other Variables condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "G" Clinical Trials Conditions > Gubbio Study Five-year Follow-up: Lithium Countertransport, Blood Pressure, and Other Variables  Gubbio Study Five-year Follow-up: Lithium Countertransport, Blood Pressure, and Other Variables
Gubbio Study Five-year Follow-up: Lithium Countertransport, Blood Pressure, and Other Variables
For Condition: Cardiovascular Diseases,Heart Diseases,Hypertension,Coronary Disease
Status: Completed
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) , Merck Research Laboratories
Synopsis: To conduct a five-year follow-up of the population of Gubbio, a town in north central Italy, in order to determine the relationship of baseline sodium-stimulated lithium countertransport to subsequent change in blood pressure and incidence of hypertension.
Details: BACKGROUND: The field work of the baseline or prevalence phase of the Gubbio Study on the Epidemiology of Hypertension was conducted between March 1983 and December 1985. The population sample included all individuals age 5 and over residing in the town of Gubbio. The survey involved a standardized comprehensive examination focussed on traits previously shown to be related to hypertensive and/or other adult cardiovascular diseases, and on other traits of current concern as possible risk factors. This latter category included measurement of red blood cell electrolyte concentrations and fluxes, particularly sodium-stimulated lithium countertransport. The study was planned, organized, and conducted by the Merck, Sharp and Dohme Center for Epidemiologic Research in cooperation with Gubbio civic and medical leaders, and with laboratory facilities in Gubbio, Naples, and Rome. Follow-up examinations were conducted in the Centro di Medicina Preventiva in Gubbio which was furnished and equipped by Merck, Sharp and Dohme of Rome, Italy. Additional work was conducted at the Center for Epidemiologic Research of Merck, Sharp and Dohme in Rome, at the University of Naples, and at Northwestern University in Chicago. DESIGN NARRATIVE: This prospective study re-examined the 5,500 residents of Gubbio who took part in the Gubbio Population Study in 1983-1985. The data collected on follow-up focused mainly on factors related to change in blood pressure and development of hypertension and included standard physical examination, height, weight, girth, blood pressure, medical history and family medical history, urine collection for study of electrolyte excretion, venipuncture, 12-lead electrocardiogram, m-mode echocardiogram, pulse, skinfold measurement, carbon monoxide content of exhaled breath, sociodemographic data on age, marital status, education, and employment, and life style data on diet, alcohol intake, smoking, and physical activity. Measurements made at baseline permitted assessment of whether the hypothesized positive relation of lithium countertransport to blood pressure was independent of such factors as age, sex, body mass index, alcohol intake, plasma uric acid, glucose, family history, and other variables generally associated with blood pressure. The relationship between 5-year changes in these factors, change in lithium countertransport, and in blood pressure were also examined. Several additional important unresolved questions on the epidemiology of blood pressure and hypertension were explored: the role of macronutrients and micronutrients in lithium countertransport and its change; red blood cell sodium and potassium concentrations and their relation to blood pressure; possible differences in calcium metabolism between hypertensives and normotensives; genetic polymorphisms related to lipid-lipoprotein metabolism and possible influence on blood pressure; patterns of blood pressure change in the elderly, the 639 and 341 persons age 65-74 and over 75, respectively, at baseline. Coronary heart disease incidence was also studied.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Male
Protocol Entry Criteria: No eligibility criteria
Total Enrollment:
Location and Contact Information:
Additional Information:
Study ID Numbers: 1112;
Study Start Date: August 1988
Record last reviewed: June 2000
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00005232
Other Heart Diseases Studies:
1. Consequences and Correlates of Weight Fluctuations
2. A Trial of CS-747 Compared with Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention (PCI)
3. Minnesota Heart Health Program
4. Dietary Intervention Methods for Clinical Trials
5. Women's Health Initiative (WHI)
Related Studies:
Other Heart Diseases Clinical Trials
Other Clinical Trials
Other Clinical Trials
Gubbio Study Five-year Follow-up: Lithium Countertransport, Blood Pressure, and Other Variables
|
|
|
|
|
|
|
|
